OpenLB
Open Library of Bioscience
Advanced Search
Breast cancer (Tokyo, Japan)
May, 2020;27 (3): 355-362.

DNA damage repair functions and targeted treatment in breast cancer.

Chenfeng He, Kosuke Kawaguchi, Masakazu Toi
Author Information
  1. Chenfeng He: Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
  2. Kosuke Kawaguchi: Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. kkosuke@kuhp.kyoto-u.ac.jp.
  3. Masakazu Toi: Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
PMID: 31898156 DOI: 10.1007/s12282-019-01038-2

Abstract

Cell DNA is continuously attacked by endogenous and exogenous agents, which causes DNA damage. During long-term evolution, complex defense systems for DNA damage repair are formed by cells to maintain genome stability. Defects in the DNA damage repair process may lead to various diseases, including tumors. Therefore, DNA damage repair systems have become a new anti-tumor drug target. To date, a number of inhibitors related to DNA damage repair systems have been developed, particularly for tumors with BRCA1 and BRCA2 mutations. Poly (ADP-ribose) polymerase inhibitors developed by synthetic lethality are widely used in individualized tumor therapy. In this review, we briefly introduce the mechanisms underlying DNA damage repair, particularly in breast cancer, and mainly focus on new treatments targeting the DNA damage repair pathway in breast cancer.

Keywords

BRCA1/2 DNA damage repair PARP inhibitor Synthetic lethality

References

  1. Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk A, Wong KK. Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Ther Adv Med Oncol. 2018;10:1758835918808509. [PMID: 30542378]
  2. Ali R, Rakha EA, Madhusudan S, Bryant HE. DNA damage repair in breast cancer and its therapeutic implications. Pathology. 2017;49(2):156–65. [PMID: 28034453]
  3. Majidinia M, Yousefi B. DNA repair and damage pathways in breast cancer development and therapy. DNA Repair (Amst). 2017;54:22–9. [PMID: 28437752]
  4. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol. 2010;4(3):255–66. [PMID: 20434415]
  5. Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med. 2001;7(5):552–6. [PMID: 11329055]
  6. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist. 2007;12(2):142–50. [PMID: 17296808]
  7. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82. [PMID: 11832208]
  8. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 2009;69(8):3625–33. [PMID: 19336573]
  9. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110–20. [PMID: 26775620]
  10. Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(40):e4975. [PMID: 27749552]
  11. Egawa C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics. Jpn J Cancer Res. 2001;92(6):624–30. [PMID: 11429050]
  12. Guo XJ, Yang CY, Qian XL, Lei T, Li YQ, Shen HF, et al. Estrogen receptor alpha regulates ATM expression through miRNAs in breast cancer. Clin Cancer Res. 2013;19(18):4994–5002. [PMID: 3778106]
  13. Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER. Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell. 2009;20(14):3374–89. [PMID: 19477925]
  14. Kim HJ, Min A, Im SA, Jang H, Lee KH, Lau A, et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int J Cancer. 2017;140(1):109–19. [PMID: 27501113]
  15. Talib WH, Al-Hadid SA, Ali MBW, Al-Yasari IH, Ali MRA. Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action. Breast Cancer (Dove Med Press). 2018;10:207–17. [PMID: 30568488]
  16. Maeda T, Nakanishi Y, Hirotani Y, Fuchinoue F, Enomoto K, Sakurai K, et al. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med Mol Morphol. 2016;49(1):11–21. [PMID: 26009308]
  17. Abdel-Fatah T, Arora A, Agarwal D, Moseley P, Perry C, Thompson N, et al. Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. Breast Cancer Res Treat. 2014;146(2):309–20. [PMID: 24972688]
  18. Janatova M, Kleibl Z, Stribrna J, Panczak A, Vesela K, Zimovjanova M, et al. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidem Biomar. 2013;22(12):2323–32. [DOI: 10.1158/1055-9965.EPI-13-0745-T]
  19. Li J, Li M, Chen P, Ba Q. High expression of PALB2 predicts poor prognosis in patients with advanced breast cancer. FEBS Open Bio. 2018;8(1):56–63. [PMID: 29321957]
  20. Verlinden L, Bempt IV, Eelen G, Drijkoningen M, Verlinden I, Marchal K, et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER-2- Breast carcinomas. Can Res. 2007;67(14):6574–81. [DOI: 10.1158/0008-5472.CAN-06-3545]
  21. Alshareeda AT, Negm OH, Aleskandarany MA, Green AR, Nolan C, TigHhe PJ, et al. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Res Treat. 2016;159(1):41–53. [PMID: 27464795]
  22. Alshareeda AT, Negm OH, Albarakati N, Green AR, Nolan C, Sultana R, et al. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast Cancer Res Treat. 2013;139(2):301–10. [PMID: 23624778]
  23. Sultana R, Abdel-Fatah T, Abbotts R, Hawkes C, Albarakati N, Seedhouse C, et al. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res. 2013;73(5):1621–34. [PMID: 23253910]
  24. Rybarova S, Vecanova J, Hodorova I, Mihalik J, Cizmarikova M, Mojzis J, et al. Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer. Med Sci Monitor. 2011;17(12):354–63. [DOI: 10.12659/MSM.882121]
  25. Faraoni I, Graziani G. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel). 2018;10(12):E487. [PMID: 30518089]
  26. Amir E, Seruga B, Serrano R, Ocana A. Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev. 2010;36(7):557–65. [PMID: 20385443]
  27. Sunada S, Nakanishi A, Miki Y. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer. Cancer Sci. 2018;109(4):893–9. [PMID: 29427345]
  28. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. [PMID: 15829967]
  29. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7. [PMID: 15829966]
  30. McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, et al. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res. 2014;16(2):R25. [PMID: 24625110]
  31. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–20. [PMID: 28167507]
  32. Griguolo G, Dieci MV, Guarneri V, Conte P. Olaparib for the treatment of breast cancer. Expert Rev Anticancer Ther. 2018;18(6):519–30. [PMID: 29582690]
  33. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33. [PMID: 28578601]
  34. Le D, Gelmon KA. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. Expert Rev Clin Pharmacol. 2018;11(9):833–9. [PMID: 30118334]
  35. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92. [PMID: 23810788]
  36. Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP inhibitors in breast cancer. Curr Treat Options Oncol. 2018;19(5):21. [PMID: 29644491]
  37. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728–37. [PMID: 17473206]
  38. Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, et al. A randomized phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol. 2017;13(4):307–20. [PMID: 27739325]
  39. Rugo HS, Olopade OI, DeMichele A, Yau C, van Veer LJ, Buxton MB, et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016;375(1):23–34. [PMID: 27406347]
  40. Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, et al. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res. 2017;19(1):99. [PMID: 28851423]
  41. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017;3:31. [PMID: 28948212]
  42. Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(7):723–30. [PMID: 27002934]
  43. Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, et al. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer. 2017;116(7):884–92. [PMID: 28222073]
  44. Nicolas E, Bertucci F, Sabatier R, Goncalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel). 2018;10(12):E506. [PMID: 30544963]
  45. McCann KE. Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. Curr Opin Obstet Gynecol. 2019;31(1):12–7. [PMID: 30540581]
  46. Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013;229(3):422–9. [PMID: 23165508]
  47. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008–155. [PMID: 21709188]
  48. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137–54. [PMID: 26463832]
  49. Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, et al. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. Gynecol Oncol. 2018;148(2):281–5. [PMID: 29233532]
  50. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 2001;276(45):42462–7. [PMID: 11571274]
  51. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9(8):616–27. [PMID: 18594563]
  52. Albarakati N, Abdel-Fatah TMA, Doherty R, Russell R, Agarwal D, Moseley P, et al. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Mol Oncol. 2015;9(1):204–17. [PMID: 25205036]
  53. Li K, Yan HY, Guo WH, Tang M, Zhao XY, Tong AP, et al. ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin. Exp Cell Res. 2018;366(1):24–33. [PMID: 29522753]
  54. Sundar R, Brown J, Russo AI, Yap TA. Targeting ATR in cancer medicine. Curr Prob Cancer. 2017;41(4):302–15. [DOI: 10.1016/j.currproblcancer.2017.05.002]
  55. van Oorschot B, Granata G, Di Franco S, ten Cate R, Rodermond HM, Todaro M, et al. Targeting dna double strand break repair with hyperthermia and DNA-PKcs inhibition to enhance the effect of radiation treatment. Oncotarget. 2016;7(40):65504–13. [PMID: 27602767]
  56. Zhang ZW, Sun CF, Zhang L, Chi XM, Ji JM, Gao XJ, et al. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin. Biomed Pharmacother. 2019;109:1541–6. [PMID: 30551406]
  57. Alsubhi N, Middleton F, Abdel-Fatah TM, Stephens P, Doherty R, Arora A, et al. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Mol Oncol. 2016;10(2):213–23. [PMID: 26459098]

MeSH Term

Antineoplastic Agents
Biomarkers, Tumor
Breast Neoplasms
DNA Damage
DNA Repair
Female
Humans
Molecular Targeted Therapy

Chemicals

Antineoplastic Agents
Biomarkers, Tumor
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0DNAdamagerepairsystemsbreastcancertumorsnewinhibitorsdevelopedparticularlylethalityCellcontinuouslyattackedendogenousexogenousagentscauseslong-termevolutioncomplexdefenseformedcellsmaintaingenomestabilityDefectsprocessmayleadvariousdiseasesincludingThereforebecomeanti-tumordrugtargetdatenumberrelatedBRCA1BRCA2mutationsPolyADP-ribosepolymerasesyntheticwidelyusedindividualizedtumortherapyreviewbrieflyintroducemechanismsunderlyingmainlyfocustreatmentstargetingpathwayfunctionstargetedtreatmentBRCA1/2PARPinhibitorSynthetic

Similar Articles

Cited By